| Teng, Gaojun |
AK104-308, NCT06371157: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 3 | 469 | RoW | AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib | Akeso | Hepatocellular Carcinoma | 10/25 | 05/26 | | |
| Active, not recruiting | 3 | 92 | RoW | TheraSphere™ Yttrium-90 Glass Microspheres, conventional Transarterial Chemoembolization(cTACE) | Boston Scientific Corporation | Inoperable Hepatocellular Carcinoma | 02/26 | 10/26 | | |
| Recruiting | 1/2 | 60 | RoW | Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres | Zhongda Hospital | Unresectable Colorectal Liver Metastases | 12/24 | 12/24 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT04520906: To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer |
|
|
| Recruiting | N/A | 139 | RoW | microwave ablation | Suzhou Hengruihongyuan Medical Technology Co. LTD | Hepatocellular Carcinoma | 01/23 | 12/23 | | |
NCT05673668: Endovascular Denervation (EDN) for the Treatment of Type 2 Diabetes Mellitus |
|
|
| Recruiting | N/A | 30 | RoW | Endovascular Denervation System (Netrod) | Zhongda Hospital | Type 2 Diabetes Mellitus (T2DM) | 10/23 | 04/24 | | |
NCT06669377: TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT. |
|
|
| Recruiting | N/A | 444 | RoW | | Zhongda Hospital | Hepatocellular Carcinoma | 01/25 | 03/25 | | |
NCT05956860: Radial Access for Abdominopelvic Vascular Intervention |
|
|
| Recruiting | N/A | 1143 | RoW | abdominopelvic vascular intervention through the radial artery access | Zhongda Hospital, Terumo Medical Corporation | Vascular Access Device Complications | 12/24 | 12/25 | | |
